BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38716756)

  • 1. Enhanced MRI Radiomics Based Model for Predicting Recurrence or Metastasis of Nasopharyngeal Cancer (NC) Undergoing Concurrent Chemoradiotherapy: A Retrospective Study.
    Song L; Liu J; Shang Y; Hu Y; Zhang J; Ye Y; Ji X; An P
    Cancer Control; 2024; 31():10732748241250208. PubMed ID: 38716756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic modeling for nasopharyngeal carcinoma (NC) undergoing concurrent chemoradiotherapy using clinical and enhanced MRI-Delta radiomics data: A preliminary study.
    Wang Q; An P; Song L; Liu J; Liu J
    Technol Health Care; 2024 Feb; ():. PubMed ID: 38517817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma.
    Zhang LL; Huang MY; Li Y; Liang JH; Gao TS; Deng B; Yao JJ; Lin L; Chen FP; Huang XD; Kou J; Li CF; Xie CM; Lu Y; Sun Y
    EBioMedicine; 2019 Apr; 42():270-280. PubMed ID: 30928358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
    Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
    Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Methods for Optimal Radiomics-Based Differentiation Between Recurrence and Inflammation: Application to Nasopharyngeal Carcinoma Post-therapy PET/CT Images.
    Du D; Feng H; Lv W; Ashrafinia S; Yuan Q; Wang Q; Yang W; Feng Q; Chen W; Rahmim A; Lu L
    Mol Imaging Biol; 2020 Jun; 22(3):730-738. PubMed ID: 31338709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical spine osteoradionecrosis or bone metastasis after radiotherapy for nasopharyngeal carcinoma? The MRI-based radiomics for characterization.
    Zhong X; Li L; Jiang H; Yin J; Lu B; Han W; Li J; Zhang J
    BMC Med Imaging; 2020 Sep; 20(1):104. PubMed ID: 32873238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Prognostic Nomogram Based on Residual Tumor in Patients With Nondisseminated Nasopharyngeal Carcinoma.
    Liao PY; Dong ZY; Huang CT; Tang XR; Liu GD; Zhu-Liu ; Wu DH
    Technol Cancer Res Treat; 2020; 19():1533033820957035. PubMed ID: 32945239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local and Lymph Node Relapse of Nasopharyngeal Carcinoma: A Single-Center Experience.
    Toumi N; Ennouri S; Charfeddine I; Daoud J; Khanfir A
    Ear Nose Throat J; 2021 Sep; 100(5_suppl):795S-800S. PubMed ID: 32141322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
    Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Chemoradiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes and Prognostic Factors.
    Kong M; Lim YJ; Kim Y
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1591-1599. PubMed ID: 29936784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of delta radiomics in xerostomia after chemoradiotherapy in patients with stage III-IV nasopharyngeal carcinoma.
    Wang M; Xi Y; Wang L; Chen H; Jiang F; Ding Z
    Radiat Oncol; 2024 Feb; 19(1):26. PubMed ID: 38418994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and survival outcomes of ascending, descending and mixed types of nasopharyngeal carcinoma in the non-endemic areas of china: A propensity score matching analysis.
    Fan Y; Guan W; Huang R; Lin SY; Song Y; Lu S; Kang L; Yang Q; Lang J; Zhang P
    Cancer Med; 2020 Dec; 9(24):9315-9325. PubMed ID: 33058559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Image-based diagnosis of residual or recurrent nasopharyngeal carcinoma may be a phantom tumor phenomenon.
    Lee CC; Lee JC; Huang WY; Juan CJ; Jen YM; Lin LF
    Medicine (Baltimore); 2021 Feb; 100(8):e24555. PubMed ID: 33663063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Radiomics Signatures Between Patients with Early and Advanced T-Stage Nasopharyngeal Carcinoma Facilitate Prognostication.
    Wu S; Li H; Dong A; Tian L; Ruan G; Liu L; Shao Y
    J Magn Reson Imaging; 2021 Sep; 54(3):854-865. PubMed ID: 33830573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Usefulness of Pretreatment MR-Based Radiomics on Early Response of Neoadjuvant Chemotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma.
    Yongfeng P; Chuner J; Lei W; Fengqin Y; Zhimin Y; Zhenfu F; Haitao J; Yangming J; Fangzheng W
    Oncol Res; 2021 Mar; 28(6):605-613. PubMed ID: 33523792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study.
    Huang L; Yang Z; Kang M; Ren H; Jiang M; Tang C; Hu Y; Shen M; Lin H; Long L
    Technol Cancer Res Treat; 2023; 22():15330338231160619. PubMed ID: 37094106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.